WHAT IS CLAIMED IS:

1. Use of verapamil and mometasone in the manufacture of a medicament for treating rhinosinusitis in a subject,

wherein an effective amount of the verapamil and mometasone are to be administered to the subject in need thereof.

2. Use of verapamil and mometasone in the manufacture of a medicament for enhancing corticosteroid retention in a subject's sinonasal epithelial cells,

wherein a subject is identified to have overexpression of P-gp in the subject's sinonasal epithelial cells; and

wherein an effective amount of the verapamil and mometasone are to be administered to the subject in need thereof.

3. Use of verapamil and mometasone in the manufacture of a medicament for reducing inflammation in a subject's sinonasal epithelial cells,

wherein a subject is identified to have overexpression of P-gp in the subject's sinonasal epithelial cells; and

wherein an effective amount of the verapamil and mometasone are to be administered to the subject in need thereof.

4. The use of claim 2 or claim 3, wherein a subject is identified to have overexpression of P-gp in the subject's sinonasal epithelial cells comprises providing a sample comprising nasal secretions, preferably comprising nasal mucus, from a subject; determining a level of soluble p-glycoprotein (P-gp) in the sample; and comparing the level of P-gp in the sample to a reference level of P-gp; wherein a level of P-gp in the sample above the reference level indicates that the subject overexpresses P-gp.

5. The use of any of the preceding claims, wherein the subject has chronic rhinosinusitis (CRS) or CRS with nasal polyps (CRSwNP).

6. The use of any of the preceding claims, wherein the verapamil and mometasone are to be administered systemically.

7. The use of any of the preceding claims, wherein the verapamil and mometasone are to be administered locally to the subject's nasal passage and sinuses.

8. The use of claim 7, wherein the verapamil and mometasone are to be delivered to the subject's nasal passage and sinuses by nasal irrigation.

9. The use of claim 8, wherein the nasal irrigation is high volume, low positive pressure nasal irrigation.

10. The use of claim 9, wherein the verapamil and mometasone are to be delivered to the subject's nasal passage and sinuses by high volume, low positive pressure nasal irrigation with a saline solution.

11. The use of claim 10, wherein the saline solution is an isotonic saline solution.

12. The use of claim 10, wherein the saline solution is a hypertonic saline solution.

13. The use of claim 12, wherein the hypertonic saline solution is about a 2% w/v saline solution.

14. The use of any one of claims 1–5, wherein the verapamil and mometasone are to be administered to the subject as a verapamil and mometasone eluting implant placed in the subject's nasal passage or sinuses.

15. The use of claim 14, wherein the implant is bioabsorbable.

16. The use of any one of claims 1–5, wherein the verapamil is to be administered to the subject's nasal passage and sinuses by nasal irrigation and the mometasone is to be administered to the subject as a mometasone eluting implant placed in the subject's nasal passage or sinuses.

17. The use of any of the preceding claims, wherein the subject having rhinosinusitis was identified by endoscopy.

18. The use of any of the preceding claims, wherein the subject having rhinosinusitis was identified by computed tomography.

19. The use of any of the preceding claims, wherein the subject having rhinosinusitis was identified by observing the subject's symptoms and duration of symptoms.

20. The use of any of the preceding claims, wherein the efficacy of the treatment is to be monitored by endoscopy.

21. The use of any of the preceding claims, wherein the efficacy of the treatment is to be monitored by computed tomography.

22. The use of any of the preceding claims, further comprising monitoring the efficacy of the treatment by observing the subject's symptoms and duration of symptoms.

23. The use of any of the preceding claims, wherein any nasal polyps present in the subject are to be surgically removed.

24. The use of any of the preceding claims, wherein the verapamil and mometasone are to be administered in combination with an antibiotic.

25. The use of claim 24, wherein the antibiotic is selected from erythromycin or a pharmaceutically acceptable salt thereof, doxycycline or a pharmaceutically acceptable salt thereof, tetracycline or a pharmaceutically acceptable salt thereof, penicillin or a pharmaceutically acceptable salt thereof, beta-lactam or a pharmaceutically acceptable salt thereof, macrolide or a pharmaceutically acceptable salt thereof, fluoroquinolone or a pharmaceutically acceptable salt thereof, cephalosporin or a pharmaceutically acceptable salt thereof, and sulfonamide or a pharmaceutically acceptable salt thereof.

26. A kit for treating rhinosinusitis in a subject, said kit comprising

a pharmaceutical composition comprising an effective amount of verapamil and mometasone; and

a device for delivering the pharmaceutical composition to the subject's nasal passage and sinuses.

27. The kit of claim 28, wherein said device delivers the pharmaceutical composition to the subject's nasal passage and sinuses in a liquid, nebulized, or aerosolized form.

28. The kit of claim 26 or claim 27, further comprising an antibiotic.

29. A bioresorbable implant comprising verapamil and mometasone.